What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short version

• Because demand exploded for GLP‑1 weight-loss and diabetes drugs (semaglutide, tirzepatide, etc.), many compounding pharmacies began making and selling compounded copies. The FDA has said that making unapproved “essentially copies” of FDA‑approved GLP‑1 drugs is unlawful and unsafe, and it has escalated enforcement (warning letters, product seizures, public safety notices).
• FDA‑approved manufacturers and pharmacies dispensing the approved branded products remain legal (for example Novo Nordisk’s semaglutide products — Ozempic, Wegovy, Rybelsus — and Eli Lilly’s tirzepatide products — Mounjaro for diabetes and Zepbound for weight). Compounding pharmacies may still operate legally, but only under narrow conditions (see below).

What the FDA did and why

• The FDA warned the public about quality and safety risks with compounded GLP‑1s: unknown/incorrect potency, contamination, improper labeling, lack of sterile manufacturing controls, and possible evasion of FDA oversight.
• The agency has issued warning letters, worked with the Department of Justice and U.S. Marshals in some cases to seize products, and urged patients and clinicians to prefer FDA‑approved products.
• The legal basis: drug copies that are not approved by FDA can be considered “new drugs” and therefore subject to approval requirements. The agency has said most compounding of GLP‑1s looks like creating unapproved copies, not legitimate patient‑specific compounding.

Who is and isn’t operating legally

• Legal, broadly available option: FDA‑approved manufacturers and retail/specialty pharmacies dispensing their approved products. Examples: Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound). These go through FDA approval, manufacturing controls, and post‑market monitoring.
• Compounding pharmacies:
  • 503A (traditional compounding) pharmacies: May legally compound only in response to an individual patient prescription and when the compound is medically necessary (e.g., allergy to an ingredient). Routine mass production of a drug that is essentially a copy of an approved product is not allowed.
  • 503B outsourcing facilities (FDA‑registered): Can produce larger batches without patient‑specific prescriptions but must register with FDA, follow current Good Manufacturing Practice (cGMP), and comply with FDA requirements. A registered 503B that follows FDA rules may legally compound some drugs, but the FDA has taken action against specific facilities that produced copies of GLP‑1s.
• Many compounding pharmacies stopped offering compounded GLP‑1s after FDA statements and enforcement. Others continue but only under strict, patient‑specific circumstances or as registered 503B facilities that can demonstrate compliance.

How to tell if a supplier is legal/safe

• Prefer an FDA‑approved product dispensed by a licensed pharmacy.
• If considering a compounded product, ask the pharmacy for:
  • Evidence the product is made only for a specific, documented medical need (a patient‑specific prescription).
  • Certificate of analysis (COA) for each lot and results of sterility/potency testing.
  • Whether it’s a 503B outsourcing facility and, if so, whether they’re registered with the FDA (FDA posts a list of registered outsourcing facilities).
  • Proof of state pharmacy licensure and accreditation (NABP/VIPPS or similar).
• Check FDA warning letters/enforcement reports and your state Board of Pharmacy for any actions against the pharmacy or clinic.

What you should do (practical advice)

• If you want a GLP‑1 product, the safest route is getting an FDA‑approved product through a licensed prescriber and a reputable pharmacy or specialty pharmacy. Examples of FDA‑approved brands: Ozempic, Wegovy, Rybelsus (Novo Nordisk); Mounjaro, Zepbound (Eli Lilly); liraglutide brands like Saxenda/Victoza; dulaglutide (Trulicity) where appropriate.
• Avoid purchasing compounded GLP‑1s online or from clinics that can’t document testing, sterility, and legal authority to make the drug.
• If you already used a compounded GLP‑1 and have health concerns, contact your prescriber and report adverse events to FDA MedWatch.

If you want, I can:

• Look up current FDA enforcement actions or warning letters (I can summarize the latest FDA notices).
• Help you find local clinics, specialty pharmacies, or the FDA list of registered outsourcing facilities.